AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01925391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tono-pen XL Applanation tonometer + Ocu-film +
Study NCT04234750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell conditioned medium-derived pleiotropic factor
Description: After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
Study NCT00951223 — intervention group
Intervention type: DRUG
Intervention: Infergen® (Interferon alfacon-1)
Description: Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
Study NCT04109183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Description: The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
Study NCT04079387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOTRACHEAL TUBE + STYLET
Description: The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°
Study NCT04079387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOTRACHEAL TUBE ALONE
Description: intubating the trachea with an endotracheal tube alone
Study NCT03013257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
Study NCT01877785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: Single-ascending dose of MHAA4549A
Study NCT01877785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MHAA4549A
Study NCT02177175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT02177175 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01089816 — intervention group
Intervention type: BIOLOGICAL
Intervention: Local/Regional Public Health Notification
Description: For any H5 positive results, notification of the result to the site's local/regional public health authorities.
Study NCT00376246 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe
Study NCT02722772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
Study NCT02722772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 5 weeks
Study NCT02722772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 5 weeks
Study NCT01286701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study NCT01286701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study NCT03700268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual intervention to programme Cochlear Implant electrodes
Description: The Clinician test the 22 electrodes so that the patient is able to hear the language
Study NCT02576925 — intervention group
Intervention type: OTHER
Intervention: Clinical, ophthalmological and neurological evaluation
Description: Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
Study NCT04392869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The CRAFT program (adapted due to COVID-19)
Description: The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context.
Study NCT04392869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The MBSR program (adapted due to COVID-19)
Description: The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context.
Study NCT04671069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
Study NCT02584816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRV-PV Lot A + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
Study NCT02584816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRV-PV Lot B + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
Study NCT02584816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRV-PV Lot C + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
Study NCT02584816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROTARIX + DPT-HepB-Hib + OPV
Description: Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
Study NCT01644565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5
Study NCT04671069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
Study NCT04350801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: home-based cognitive monitoring
Description: a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
Study NCT00480207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Study NCT00480207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Study NCT01644565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Study NCT00480207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit B12
Study NCT00480207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folic acid placebo
Study NCT00480207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omega-3 placebo
Study NCT02456792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Women will undergo one IVF cycle
Study NCT01644565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Study NCT02456792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOD
Description: Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
Study NCT01721148 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ASLAN002( BMS 777607)
Description: 100mg, 200mg, 300mg, 450mg, 600mg
Study NCT01256983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: 10000 Lux for 30 Minutes according to sleep wake rhythm
Study NCT01256983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list intervention
Description: 10000 Lux for 30 Minutes according to sleep wake rhythm
Study NCT03957746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
Study NCT05529407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple Vaginal Tampon
Description: Use of single use vaginal tampons
Study NCT05529407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass Vaginal Trainer
Description: Use of glass vaginal trainers
Study NCT03429738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets
Description: Experimental drug
Study NCT03429738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets
Description: Active Comparator
Study NCT00589173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record (IPHR)
Description: Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
Study NCT00589173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard preventive care
Description: Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
Study NCT02059629 — intervention group
Intervention type: DEVICE
Intervention: Eluna pacemaker family
Description: New pacemaker generation with new functions, like wandless RF telemetry SafeSync
Study NCT02059629 — intervention group
Intervention type: DEVICE
Intervention: Sentus BP lead
Description: over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
Study NCT00780949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal biopsies
Description: intestinal biopsies during routine endoscopy
Study NCT00529100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Phase 1
Description: 300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
Study NCT01875913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curiosity Message
Description: Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
Study NCT01875913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Message
Description: Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online).
Study NCT01174888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Drug midostaurin, Given orally given twice daily days 1-14
Study NCT01174888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib given IV on days 1, 4, 8, and 11
Study NCT01174888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Patients receive mitoxantrone hydrochloride IV over 10 minutes
Study NCT01174888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Patients receive etoposide IV over 1 hour
Study NCT03840616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VT-1161) 150mg capsule
Description: 600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
Study NCT03840616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 150mg capsule
Description: 150mg administered every 72 hours in 3 sequential doses starting on Day 1.
Study NCT03840616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered once weekly starting on Day 14.
Study NCT01174888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Patients receive cytarabine IV over 6 hours on days 1-6
Study NCT03030768 — intervention group
Intervention type: DRUG
Intervention: PrEP
Description: An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
Study NCT03030768 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling on timed condomless sex, ART and PrEP adherence
Description: An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
Study NCT00270413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU11248
Description: sutent 50 mg daily 4w on 2w off
Study NCT03123510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium spp plus bimuno- galacto-oligosaccharides
Description: Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
Study NCT03123510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
Study NCT00690976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proyecto SOL
Description: Group intervention
Study NCT00690976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCT
Description: Offer of HIV counseling and testing
Study NCT00520286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg or 400 mg /daily
Study NCT00520286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo / daily
Study NCT01908816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
Study NCT02114476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: progestin implant
Description: two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
Study NCT02114476 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00529100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Phase 1
Description: Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
Study NCT00529100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Phases 1 and 2: 61-65 Gy in 33-35 fractions
Study NCT00529100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Phase 2
Description: Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
Study NCT04100785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy
Description: The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
Study NCT02468752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Study NCT02468752 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Air
Study NCT03908762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSage App with connected glucometer
Description: Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
Study NCT03908762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Magnet
Description: Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
Study NCT00778024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine HCL 40 mg capsules
Study NCT00778024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine HCL 40 mg capsules
Study NCT02633488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A 12 week single blind placebos
Study NCT02633488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: A 12 week single blind metformin
Study NCT04300010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Topical Benzoyl Peroxide Gel
Description: Gel treatment used to treat acne
Study NCT04300010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light Therapy
Description: Blue light therapy treatment for acne
Study NCT03092063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tomando Control-Nurse
Description: Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
Study NCT03092063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tomando Control-Promotora
Description: Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
Study NCT03092063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced engagement
Description: The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
Study NCT03092063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifamily Group
Description: The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions.
Study NCT01305148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warfarin GenoSTAT Test
Description: Use of genetic information from the GenoSTAT test to determine the warfarin dose
Study NCT02267278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.